Effect of Serum Ferritin Level on the Response to Standard Chemotherapy in Acute Myeloid Leukemia Patients

AuthorNasrin Namdarien
AuthorAli Ghane-Shahmirzadien
AuthorSezaneh Haghpanahen
AuthorMaral Mokhtarien
OrcidNasrin Namdari [0000-0002-1597-8787]en
Issued Date2025-11-30en
AbstractBackground: A high ferritin level in acute myeloid leukemia (AML) patients acts as a growth factor for leukemic cells, and its antioxidant effect may reduce the effectiveness of cytotoxic chemotherapy drugs, including anthracyclines. Methods: All adult patients with AML from 2013 to 2023, who had received 7+3 chemotherapy protocol at Namazi and Amir hospitals in Shiraz provided that Ferritin and C-reactive protein (CRP) level were checked before chemotherapy were included. We evaluated complete remission rate, overall survival (OS) and event-free survival (EFS) in 67 new cases. Results: The EFS was significantly longer in patients with serum ferritin levels below 1000 ng/mL compared to those with serum ferritin levels of 1000 ng/mL or higher [estimated mean and 95% CI: 25.65 (19.29 - 32) vs 11.6 (8.19 - 15.13) months, P = 0.018]. Conclusions: Ferritin levels at diagnosis are indicative of patient survival. The AML patients with serum ferritin levels greater than 1000 experienced shorter EFS compared to those with ferritin levels below 1000.en
DOIhttps://doi.org/10.5812/semj-161086en
KeywordFerritinen
Keyword7+3 Regimenen
KeywordAllogeneic Stem Cell Transplantationen
KeywordAnthracyclineen
PublisherBrieflandsen
TitleEffect of Serum Ferritin Level on the Response to Standard Chemotherapy in Acute Myeloid Leukemia Patientsen
TypeResearch Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
semj-26-11-161086-publish-pdf.pdf
Size:
282.33 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF